42 results about "Melanoma patient" patented technology

Methods to treat cancer patients, especially melanoma patients, who have BRAF mutations and have become resistant to BRAF mutant kinase inhibitors employ inhibitors of multiple receptor tyrosine kinases. In addition, methods are described for identifying pharmaceutical compositions and drugs that will be successful in treating these patients.

This invention relates to compositions comprising haptenized tumor cells and extracts thereof, methods for preparing the compositions, vaccines comprising such haptenized tumor cells, and methods for treating cancer with such vaccines. In a specific embodiment, melanoma cells are haptenized with a dinitrophenyl group, and used for treatment of melanoma patients having metastatic disease. Preferably, patients are given a first vaccine dose containing haptenized cells to “prime” the immune system. Subsequently, patients are injected with an immunomodulatory compound such as cyclophosphamide. In a preferred embodiment, an appropriate time period after the “priming” vaccine dose, additional vaccine doses containing a mixture of haptenized cells and an adjuvant are administered. The described treatment plan is more effective for eliciting favorable anti-tumor immune responses.

The invention belongs to the technical field of formulas of edible-medicinal foods and new resource foods, and particularly provides a non-total-nutrient formula food, specific total-nutrient formula food or total-nutrient formula food for patients suffering from the melanoma. The formula is made according to the requirements of the <General Rules for Formula Foods for Special Medical Purposes>, and is combined with the physical characteristics of patients suffering from the melanoma. The formula food provided by the invention is prepared by reasonably mixing various 'edible-medicinal' traditional Chinese medicines according to the quintessence theory of traditional Chinese medicine, and is prepared by mixing essences which are extracted from various edible-medicinal traditional Chinese medicines by adopting a prehydrolysis SBE technique, short peptides extracted from biological enzymolysis, prebiotics, amino acid, carbohydrate, grease with a function of keeping healthy, various vitamins and mineral substances and other technologies. The formula food can be used as a single nutrient source satisfying the nutrient demands of patients suffering from the melanoma, and has the efficacy of clearing away heat and toxic materials, removing toxic materials and blood stasis, strengthening body resistance and inhibiting cancers, benefiting qi and nourishing blood, and strengthening immunity.

The invention discloses the application of the ASMT / CYP1A1 molecular signature in predicting the clinical prognosis or immune characteristics of solid tumors. The inventors studied the transcriptome and genome data of 6,658 tumor samples from 14 kinds of solid tumors, and conducted a large-scale bioinformatics analysis, confirming that the ratio of ASMT / CYP1A1 in different solid tumors is related to the clinical prognosis and tumor mutation level of patients. , Tumor neoantigen load relationship. Among them, the clinical prognosis of cervical cancer, gastric cancer, and melanin patients in the High Index group was more impressive. The results of multivariate analysis showed that ASMT / CYP1A1 was an independent predictor of clinical prognosis in cancer patients; in addition, in colorectal cancer, head and neck squamous Among patients with cancer, kidney cancer, liver cancer, prostate cancer, and melanoma, although the prognosis of patients in the Low Index group is poor, there are more mutation loads and / or tumor neoantigens, suggesting that patients in this group are more likely to benefit from immunotherapy. benefit.

Cellular and genetic signatures and methods of using same for subcategorizing stage III melanoma tumors are described herein. The signatures and methods are particularly useful with regard to establishing more distinct criteria on which basis to differentiate stage IIIB and IIIC melanoma patients. Assessment of the cellular and genetic signatures of a melanoma sample using methods described herein yields information on which basis differential survival duration and sensitivity to various cancer therapies can be predicted for a Stage IIIB or Stage IIIC melanoma patients. As described herein, gene expression profiling, determination of mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions may be utilized to predict or assess drug response, drug sensitivity, and clinical outcome in metastatic melanoma patients.